SP-MHCI-0471-2

Survivin (BIRC5) (BIRC5) 96-104, LMLGEFLKL

US$169.00

In stock

Description

About Survivin (BIRC5) (BIRC5) 96-104, LMLGEFLKL

The Human Baculoviral IAP repeat-containing protein (BIRC) 5 (mutated sequence of LTLGEFLKL) Peptide (IEDB: 38060) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The Baculoviral IAP repeat-containing protein (BIRC) Peptide, H-LMLGEFLKL-OH (Uniprot: O15392  aa: 96-104) from JPT is produced under strict quality control and quality management.

Survivin (BIRC5) (BIRC5) 96-104, LMLGEFLKL - Specifications

  • Peptide sequence: H-LMLGEFLKL-OH
  • Amount: 1 mg
  • Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
  • Counterion: TFA
  • Delivery Format: Freeze-dried in glass vial
  • Application(s): T-cell Immunity
  • Condition(s)/Topic(s): Breast cancer, Cancer, Melanoma
  • Standard Delivery Time: approx. 3 weeks

JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Take a look at our Custom Peptide Synthesis!

Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!

References

References for Survivin (BIRC5) (BIRC5) 96-104, LMLGEFLKL

References:
Read References with JPT’s Antigen Peptides
Survivin (BIRC5) (BIRC5) 96-104, LMLGEFLKL has been described in:
Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivin., Vaccine, 2005 (PMID: 15603888)
Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8<sup>+</sup> T Cell Responses., Front Immunol, 2018 (PMID: 30631324)
Human CD8 T lymphocytes recognize Mycobacterium tuberculosis antigens presented by HLA-E during active tuberculosis and express type 2 cytokines., Eur J Immunol, 2015 (PMID: 25631937)

Documentation

Documentation for Survivin (BIRC5) (BIRC5) 96-104, LMLGEFLKL

Properties

Properties of Survivin (BIRC5) (BIRC5) 96-104, LMLGEFLKL

Properties Values
Application: T-cell immunity
Category: Antigen Peptides
Condition / Topic: Breast cancer, Cancer, Melanoma
Layout: Freeze-dried in glass vial
Organism: Human
Protein Name: Baculoviral IAP repeat-containing protein (BIRC)
Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
Quantification: No, Yes

Further Information to Survivin (BIRC5) (BIRC5) 96-104, LMLGEFLKL

Information Values
Sequence: H-LMLGEFLKL-OH
WT Sequence: LTLGEFLKL
Specifications: 9mer peptide as TFA salt
Loading...

Check our list of products, click and go.

Get a quote